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Therapeutic angiogenesis is under investigation to restore tissue perfusion in 
ischaemic heart disease and peripheral arterial disease. Insulin-like growth factor 
binding protein-2 (IGFBP-2) has been attributed with pro-angiogenic activity but the 
molecular mechanisms have not been established. Structurally, IGFBP-2 possesses 
insulin-like growth factor (IGF) binding-, integrin recognition- (Arginine-Glycine-
Aspartic Acid (RGD)) and heparin binding- sites and a nuclear localisation signal 
which may be implicated in its cellular actions. 
We hypothesise that IGFBP-2 can be exploited to promote therapeutic angiogenesis 
through cellular actions mediated by one or more of its structural domains. 
Restoration of limb perfusion was quantified by laser Doppler imaging following hind 
limb ischemia in mice expressing human IGFBP-2. Mechanistic studies were carried 
out in cultured human umbilical vein endothelial cells (HUVEC). Functional 
angiogenic responses were explored with tube formation and cell adhesion assays. 
Wild type IGFBP-2 (WTIGFBP-2) and recombinant IGFBP-2 containing a non-
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to identify the structural domain responsible for the pro-angiogenic signalling 
mechanisms. 
Transgenic expression of hIGFBP-2 in mice significantly enhanced restoration of 
blood flow to the limb at day 7 compared to WT littermates (p<0.05). Both WTIGFBP-2 
and ,*)ǻIGFBP-2, significantly increased tube formation in HUVEC. 
Interestingly, 5*'ǻIGFBP-2 stimulated tube formation was greatly decreased 
compared to WTIGFBP-2 (p<0.05). WTIGFBP-2 increased HUVEC adhesion to 
fibronectin (1.6 fold); however this effect was absent with 5*'ǻIGFBP-2. Stimulation of 
endothelial cells with WTIGFBP-2 induced Akt phosphorylation (1.3 fold). 5*'ǻIGFBP-2 
did not significantly activate Akt. Neither WTIGFBP-2 nor the mutants induced the 
canonical angiogenic signalling factors, such as eNOS, FAK or MAPK 
phosphorylation. 
IGFBP-2 promotes angiogenesis in vitro and in vivo, supporting its further 
investigation for therapeutic angiogenesis in ischaemic disorders. For the first time, 
we demonstrate that the RGD domain of IGFBP-2 appears to play a critical role in 
angiogenic activity. 
